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The ﬁrst patient with inﬂuenza A/H1N1-related pneumonia was admitted to an Italian ICU at the end of August 2009. Until then,
despitetheinternationalalarm,thelevelofawarenesswaslowandveryfewItalianhospitalswereequipped withECMOs.Moreover
the PCR test for A H1N1 virus was sporadically available and the emergency departments of even the largest institutions could
rely onlyon the rapid test for the urgent screening ofpatients with pneumonia and respiratory failure. On September 5th,a young
and “apparently” previously healthy man, was admitted to our ICU because of a severe ARDS caused by inﬂuenza A H1N1 virus.
As there was no ECMO available, he was treated with prolonged cycles of prone positioning ventilation. Antiviral treatment was
started withOseltamivir,but asenteralabsorptionwasimpaired byparalyticileus andtube feeding intolerance,Oseltamivirhadto
be discontinued. Intravenous Zanamivir 1200 mg/day for ten days was therefore prescribed as “oﬀ label” antiviral therapy. A bone
marrow biopsy allowed the diagnosis of an initial stage of “hairy cells leukaemia.”ARDS related to A/H1N1 inﬂuenza was the ﬁrst
sign of the disease in our patient. He did well with complete clearance of the infection from the BAL after 10 days of Zanamivir,
although the nasopharyngealswabs remained positive forten more days. Pronepositioning ventilation maybe a life-saverstrategy
in patients with severe ARDS when ECMO is not immediately available.However, pronepositioningventilation isoften associated
with severe impairment of the absorption of drugs that require enteral administration via the nasogastric tube. In these cases,
intravenous Zanamivir may be an eﬀective alternative strategy.
1.CaseReport
On September 5th, a 41-year-old Caucasian man was trans-
ferred to our Emergency Department (ED) from a nearby
private hospital, where he had been admitted only a few
hours before.
There was nothing relevant in his past medical history.
He was under no medication and had no history of alcohol
ordrug abuse.Hisbody weight and height were, respectively,
90Kg and 190cm.
Three daysearlier, hecalled theoutpatientdepartment of
a district hospital complaining of high fever (40◦C), cough,2 Critical Care Research and Practice
and myalgia. In spite of a chest X-ray showing bilateral
inﬁltrates, he was sent home on antibiotics with no further
investigations prescribed.
In the next three days, he worsened progressively. On
admission to our ED, he was dyspnoeic and hypoxic with
respiratory fatigue, tachycardia, and systolic hypertension.
Blood gas analysis on admission showed severe hypox-
emia, hypercarbia, and respiratory acidosis.
He was given high-ﬂow oxygen; blood cultures were
performed as well as a pharyngeal swab for an H1N1 rapid
test. The urines were tested for Streptococcus Pneumoniae
and Legionella free antigens.
The chest CT scan showed “ground glass” bilateral
inﬁltrates involving the dependent regions of both lungs,
suggesting ARDS pneumonia related.
After sedation, the patient’s trachea was intubated. A
tracheal aspirate was sent for Gram staining and culture.
Antibiotic therapy was modiﬁed and diﬀerent drugs were
prescribed according to the local guidelines for “non-
responding pneumonia” (Piperacillin/Tazobactam + Van-
comycin + Levoﬂoxacin).
Bacterial urinary antigens were negative as well as the
Gram stain on the tracheal aspirate. The A virus H1N1
rapid test (Binax-Now, Inverness Medical, Southgate, Maine,
USA) was performed on admission to the ED and repeated
12 hours later. Both tests were negative. The patient was
admitted to our ICU.
On admission to the ICU, the patient was sedated
and artiﬁcially ventilated. Blood Pressure (90/50) was sup-
ported with vasopressors (Norepinephrine 9mcg/Kg/min)
and hynotropic agents (Dobutamine 28mcg/Kg/min). Uri-
nary output was preserved. Body temperature was 39◦C. On
peripheral blood sample, leukopenia (<700) was recorded.
A Pressure Control Ventilation-Volume Guaranteed
(PCV-VG) with protective lung strategy (8ml/Kg) was
started.
The initial P/F was as low as 84, and increasing oxygen
concentrations were required.
Positive End Expiratory Pressure (PEEP) was set up to
16cmH2O(best PEEP)withonlyslight improvement.In the
next few hours, haemodynamic monitoring with PiCCO was
started, and Trans-Thoracic Echocardiography (TTE) was
performed.
TTE showed preserved global systolic function, high
right ventricular telesystolic pressure despite right ventricle
normal thickening with paradoxical septal motion, and
limited tricuspid regurgitation.
These results were consistent with the data of PiCCO
(low cardiac index, high total peripheral resistances, high
lung water, low preload volume, and high stroke volume
variation).
During the patient ICU stay, serum creatinine was in a
normal range (0.5–1.5mg/dL)demonstrating a normal renal
function.
Sedationwas obtainedusing midazolam 5mg/h plusfen-
tanyl 0.15mg/h continuously to achieve a Ramsay score 3-4.
A bone marrow biopsy was performed to investigate
the severe leukopenia as well as a new BAL. BAL samples
were sent for culture and for nucleic acid testing for
Legionella, Chlamydia, Cytomegalovirus, inﬂuenza virus,
and Pneumocystis Carinii, together with nasopharyngeal
swabs for inﬂuenza RT-PCR.
Because of further worsening in hypoxemia, prone
positioning was started after inducing more deep sedation
and muscular paralysis using Vecuronium Bromidii 2mg/h
continuously. The prone position was associated with a
signiﬁcant improvement in the gas exchange as well as
with a sharp amelioration in the patient’s haemodynamics
(Figure 1). At the same time, enteral nutrition (1Kcal/mL–
1000mL/q.d.) and hydration (1000mL/q.d.) were used as a
conservative strategy ﬂuids intake; antithrombotic therapy
(LMWH 4000Usc/q.d.), methylprednisolone (1.0mg/kg 6
i.d.) were started. Each time the patient was turned back to
the supine position (as we planned to do every 12 hours),
a fast deterioration in the P/F was observed together with
worsening of the cardiac output and of the patient’s haemo-
dynamics. Therefore, prolonged cycles of prone positioning
ventilation were alternated with short intervals in supine.
On day 3, inﬂuenza virus A(H1N1)v was identiﬁed by a
qualitative RT-PCR (CDC protocol of real-time RT-PCR for
inﬂuenza A(H1N1), WHO April 2009) in nasopharyngeal
swabs. Oseltamivir 75mg bid was started via nasogastric
tube (NGT) accordingly with the suggested dose from
pharmaceutical company.
The patient showed a progressive haemodynamic
improvement, and while kept in the prone position he could
be weaned from hynotropic agents and vasopressors. In the
supine position, Cardiac Output still required dobutamine
support.
However, prone position maintenance needed deep
sedation and muscular paralysis for most of the time. In
our opinion, gastric distension refractory to prokinetics,
vasopressors and GI edema due to SIRS, and tube feeding
intolerance made the administration of Oseltamivir via
nasogastric tube unreliable rather than prone position itself.
The bone marrow biopsy showed an early stage of “hairy
cells” leukaemia. There were no signs or symptoms of the
disease in the recent patient’s medical history. A routine
blood analysis only a few months before was completely
normal. No speciﬁc therapy was prescribed but lenograstim
(Granulocyte). WBC count raised up from 350/mm3 to
4000/mm3 within 5 days. On day 11 and 12, he could be kept
supine 24 hours a day.
On day 8, the temperature increased and the respiratory
patterns worsened. A new qualitative RT-PCR turned out
positive for virus A(H1N1)v. The dosage of Oseltamivir was
doubled (150mg × 2). Prone positioning had to be started
again, andaPEEPupto20cmH2Owasrequired.Onceagain
feeding intolerance and vomiting hampered the nasogastric
administration of Oseltamivir.
On day 11, another qualitative pharyngeal swab showed
a persistence of the inﬂuenza virus A(H1N1)v. Resistance
testing was performed on day 12 by direct sequencing of a
signiﬁcant portion of thewholegene:nosingle mutationwas
detected compared to the sequence from the day 2 sample,
either at critical sites or anywhere in the sequence. As the
patient still needed to be ventilated in prone position, we
decided to discontinue oral Oseltamivir. The permission toCritical Care Research and Practice 3
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Figure 1: Correlation among P/F values in supine and prone positions, PEEP levels, and ventilation modalities.
use Zanamivir via the intravenous route to avoid gastric
intolerance was requested to the patient’s relatives and the
HospitalEthicalCommittee.The “oﬀlabel”useofZanamivir
600mg IV bid for 10 days was authorized, and the drug was
started on day 13.
During the following days the patient slightly improved.
All bacteriological investigations (blood, urines, and
tracheo-aspirates) were negative throughout the ICU stay
with the exception of a single isolate of candida albicans
from a central venous line. Percutaneous tracheostomy
was performed on day 16, as soon as patient’s oxygenation
improved enough to allow this procedure to be safely
performed. On day 13, the ventilation was shifted from
Pressure Controlled to Airway Pressure Released Ventilation
(APRV) and subsequently to Pressure Support with a
progressive decrease in the levels of PEEP and FiO2.O n c e
sedation was discontinued, eﬀective spontaneous ventilation
(Sp.Breath.)wasrestoredwithgoodrecoveryofautonomous
respiratory function. Figure 1 shows the trend in P/F and
duration of any ventilation setting we used.
Since inﬂuenza virus persisted in respiratory swabs, a
new resistance test was performed on day 18, but this time
analyzing most of the neuraminidase gene sequence again
without any mutation detected.
On day 22, a bronchoalveolar lavage (BAL) sent for virus
A(H1N1) was negative. Zanamivir was discontinued. The
tracheostomy was closed, and the patient was transferred to
theward.Eightdayslater,onOctober10th,hewassenthome
and subsequently followed as an outpatient.
During the patient ICU stay, all the BAL and nose-
throat samples were analyzed by a qualitative real-time PCR.
Subsequently, the ampliﬁcation curves were quantitatively
reevaluated with the aid of an external calibration curve
standardized on the positive control (a series of aliquots
of the same material from an in vitro culture, used in all
sessions), in order to determine the viral load dynamics
in respiratory samples and how it was inﬂuenced by the
treatment. Figure 2 shows the modiﬁcation in the viral load
during the ICU stay.
2.Discussion
Death from inﬂuenza A(H1N1)vpneumonia is related to the
onset of ALI-ARDS [1, 2].
Although our young patient had a negative medical his-
tory,hehadanunderlyinglymphoproliferativedisease which
may explain why pneumonia rapidly worsened evolving to
such a severe ARDS [3–6].
In our experience, the use of Oseltamivir through the
nasogastric route was associated to a 20-fold reduction
of viral load in nasopharyngeal secretions, as shown in
Figure 2. It is interesting to note that in our case Oseltamivir
w a ss t a r t e do nd a y3b e c a u s eo faf a l s en e g a t i v er e s u l t
derived from a quick virus test. However, the role of the
drug could not be demonstrated as the viral load could
unfortunately only be evaluated “a posteriori”. For this
reason, we interpreted the persistence of the positive tests on
days 8 and 11 as the consequence of suboptimal absorption
of Oseltamivir. Indeed, the inﬂammatory response aﬀecting
also the gastrointestinal mucosa and the combination eﬀect
of deep sedation/paralysis and prone position severely
delayed peristalsis (high-volume gastric aspirates), possibly4 Critical Care Research and Practice
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Figure 2: Modiﬁcations of the viral charge during treatment with
oral Oseltamivir and parenteral Zanamivir.
impairing drug absorption. For these reasons, we decided to
treat the patient with parenteral Zanamivir.
In our experience, intravenous Zanamivir (aqueous
solution) was safe [7–9]. The administration of Zanamivir
(1200mg/day for ten days) was associated with a progressive
clinical recovery followed by the complete eradication of
the virus from the BAL. A similar result was observed
by Kidd et al. [9]. However, Zanamivir was unable to
clear or reduce viral load from nasopharyngeal secretions
during treatment. It is therefore questionable whether viral
clearance in BAL was a simple chronological association or
the genuine antiviral eﬀect of intravenous Zanamivir. As the
“oﬀ label” therapy with Zanamivir was only authorized for
ten days, the drug was discontinued before complete viral
clearance was achieved.
Zanamivir in aqueous solution is still unlicensed. This
leads to diﬃculties in the drug supply and to the need
of speciﬁc authorization before its administration: we used
Zanamivir in agreement and under the supervision of the
Hospital Ethical Committee.
As we know, there is a mounting evidence that ECMO
mayimprovesurvivalinpatientssuﬀeringARDSfromH1N1
inﬂuenza [10].
Before the onset of the inﬂuenza A(H1N1)v pandemic,
the use of ECMO in Italy was limited to a few institutions,
and even many tertiary care hospitals were not equipped
with ECMO. Other European countries may face a similar
situation as not a single patient with A H1N1 virus-
related respiratory failure was treated with ECMO in Spain
according to the recent paper from Rello et al. [11]. An
ongoing Italian national program will probably bring a fast
diﬀusion of ECMOs as a tool to treat patients with ARDS
caused by A(H1N1)v.
Once a patient presents with a very severe ARDS, there
may be major problems to refer him to other hospitals as
prolonged transportation may be extremely dangerous. In
these cases, an experienced team may eﬀectively provide an
adequate respiratory support by means of a protective lung
strategy and a wise use of the PEEP. In our experience,
prolonged cycles of prone positioning ventilation have been
the key to ensure a proper oxygenation and ameliorate
cardiac output.
Our patient was submitted to prolonged cycles (at least
12h hours each) of prone positioning ventilation for as
long as 15 days. Very often the interval between two cycles
of prone positioning could not be longer than two hours
to avoid gas exchange deterioration and the worsening
of patient’s haemodynamics. The PEEP was continuously
adjusted looking for the best PEEP. Tidal volume was
strictly maintained within the 6–8ml/kg range. Airway
pressure release ventilation was started as soon as possible to
reduce the risk of baro/volutrauma. Methylprednisolone was
administered since day 2 and throughout the ICU stay.
There is no consensus in the literature as for the use and
dosage of steroids in virus A H1N1 pneumonia and steroids
are not included in the treatment guidelines [12].
However, a few controlled trials and at least one meta-
analysis support the use of corticosteroids in ARDS [13].
Steroids used early and in doses not exceeding 1mg/kg/day
may improve mortality and reduce ICU length of stay.
According to Meduri et al. [13], steroids may even decrease
bacterialsuperinfections throughareductionoflunginﬂam-
mation.
In addition, the best critical care standards (haemo-
dynamics, diuresis, ﬂuid balance, sedation, nutrition, and
infections prevention) have a dramatic relevance to avoid
further complications and prevent mortality.
Although there are no deﬁnitive recommendations for
the treatment of patients with severe lung injury related to
virus A/H1N1 infection, these patients should be probably
managed not diﬀerently from patients with ARDS due to
othercauses. The antiviral drugsarerecommendedtoreduce
viral concentration.There are no dataaboutthe eﬀectiveness
of the diﬀerent antiviral agents. Drug absorption may be
important toensureeﬀectivebloodlevelsoftheadministered
antiviral drug. In our experience, feeding intolerance might
impair enteral absorption, intravenous Zanamivir was an
eﬀective substitute for oral Oseltamivir.
3.Conclusions
Prone positioning ventilation may be a life-saver strategy in
patients with severe ARDS when ECMO is not immediately
available. However, prone positioning ventilation is often
associated with severeimpairment oftheabsorption ofdrugs
that require enteral administration via the nasogastric tube.
In these cases, intravenous Zanamivir may be an eﬀective
alternative.
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